Commercial Tryngolza charts blockbuster course after FDA’s hypertriglyceridemia approval Pharmaceutical TechnologyIonis has forecast peak sales of $2bn for Tryngolza as it seeks to harness first-mover advantage.CardiovascularRead full story pharminent June 26, 2026 (Last updated: July 1, 2026) Pharmaceutical Technology Ionis has forecast peak sales of $2bn for Tryngolza as it seeks to harness first-mover advantage. Cardiovascular Read full story Post navigation Previous: Ionis grants Recordati rights to zilganersen for Alexander diseaseNext: Immunai and Boehringer partner to identify T-cell targets Related Stories Commercial Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand pharminent September 14, 2026 Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026